



AYRTON DRUG MANUFACTURING LTD

UNAUDITED STATEMENT OF FINANCIAL POSITION AS AT 30TH SEPTEMBER 2019

	Notes	30/09/2019 GH¢	30/09/2018 GH¢
Non current assets			
Property, plant and equipment	3	6,032,844	6,893,922
Prepaid lease and land		353,654	362,368
Intangible		317,803	-
Deferred tax assets		557,627	210,893
		<u>7,261,927</u>	<u>7,467,183</u>
Current assets			
Inventories	4	9,570,624	10,721,312
Trade and other receivable	5	15,003,839	14,588,328
Amount due to/from Associated company		3,171,196	4,904,867
Current taxation		-	-
Cash and bank	6	79,439	1,182,992
Total Current Assets		<u>27,825,098</u>	<u>31,397,499</u>
Total Assets		<u>35,087,024</u>	<u>38,864,682</u>
Equity and liabilities			
Equity			
Issued capital		4,475,000	4,475,000
Other capital reserve		1,739,436	1,739,436
Income surplus		10,932,618	17,115,182
		<u>17,147,054</u>	<u>23,329,618</u>
Current liabilities			
Trade and other payable	7	6,343,503	8,406,571
Amount due to Associated Company		1,036,406	-
Income tax payable		1,595,273	602,995
Short term borrowings	8	8,964,789	6,525,498
Total Liabilities		<u>17,939,971</u>	<u>15,535,064</u>
Total Equity and liabilities		<u>35,087,024</u>	<u>38,864,682</u>

Director
Daniel Apegyei Kissi

Chairman
Nik Amarteifio

**NOTES TO THE CONDENSED FINANCIAL STATEMENTS
FOR THE PERIOD ENDED 30TH SEPTEMBER, 2019**

	2019	2018
9 COST OF SALES	GHC	GHC
Raw Materials and consumables	2,734,319	1,148,486
Production Wages/Salaries	954,442	635,541
Depreciation-Production	66,691	63,969
Production Overhead	462,119	662,185
	4,217,571	2,510,182
	-	
10 Other Income	2019	2018
	GHC	GHC
Sundry Income	67,121	5,794
Disposal Profit	49,000	-
	116,121	5,794
11 SELLING AND DISTRIBUTION COST	2019	2018
	GHC	GHC
This includes		
Employee benefit	271,165	260,465
SSNIT contribution	32,006	31,352
Motor Vehicle cost	66,052	121,770
Depreciation and Amortisation	66,691	40,135
Carriage	26,944	123,891
12 GENERAL AND ADMINISTRATION COST	2019	2018
This Includes:	GHC	GHC
Director Emoluments		82,013
Employees Benefit other than SSNIT Contribution	782,686	625,635
SSNIT contribution	99,084	57,596
Audit fees & Expenses	67,222	25,187
Staff Bonus	120,000	120,000
Consultancy Charges	27,269	69,628
Communication & Postage	80,029	123,378
Depreciation and Amortisation	40,721	21,648
Bad Debts Provision	60,000	60,000
13 Finance costs	2019	2018
	GHC	GHC
Interest on short-term borrowings	503,304	342,793

AYRTON DRUG MANUFACTURING LTD
UNAUDITED STATEMENT OF
PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME
FOR THE FIRST QUARTER ENDED 30TH SEPTEMBER 2019

		30/09/2019	30/09/2018
	Notes	GHC	GHC
Revenue		5,605,189	6,566,028
Cost of sales	9	(4,217,571)	(2,510,182)
Gross profit		1,387,618	4,055,846
Other income	10	67,121	5,794
Exchange Gain/(Loss)		66,349	(156,211)
Selling and distribution costs	11	(524,191)	(669,218)
Administrative expenses	12	(1,745,623)	(2,005,887)
Operating Profit/(loss)		(748,726)	1,230,324
Finance income		(7,704)	-
Finance costs	13	(495,600)	(342,793)
Profit/(loss) before tax		(1,252,030)	887,531
Income tax expense		-	(203,081)
Profit/(loss) after tax		(1,252,030)	684,450
Earnings per share		(0.0058)	0.01682
Diluted earnings per share		(0.0058)	0.01682

AYRTON DRUG MANUFACTURING LTD

UNAUDITED STATEMENT OF CHANGES IN EQUITY FOR THE FIRST QUARTER ENDED 30TH SEPTEMBER 2019

	Stated capital GH¢'000	Retained Earnings GH¢'000	Other Reserves GH¢'000	Total GH¢'000
Period ended 30th September, 2019				
At 1 JULY 2019	4,475,000	12,184,648	1,739,436	18,399,084
Profit/(Loss) for the period	-	(1,252,030)	-	(1,252,030)
Reversal during the period	-	-	-	-
At 30th September 2019	4,475,000	10,932,618	1,739,436	17,147,054
				-
	GH¢'000	GH¢'000	GH¢'000	GH¢'000
Period ended 30th September, 2018				
At 1 JULY 2018	4,475,000	16,227,651	1,739,436	22,442,087
Profit/(Loss) for the period	-	384,450	-	384,450
Reversal during the period	-	-	-	-
At 30th September, 2018	4,475,000	16,612,101	1,739,436	22,826,537

